By dissecting the mechanistic roles of these targets and the evidence supporting their combination with menin inhibitors, we aim to provide a comprehensive overview of the emerging therapeutic landscape for KMT2Ar AML and propose novel strategies to enhance treatment efficacy and overcome resistance. Here, MEN1 is linked to acute myeloid leukemia.